Abvc biopharma provides adhd phase ii part 2 clinical study update and announces ucsf institutional review board approval

Freemont, ca, sept. 23, 2022 (globe newswire) -- via newmediawire -- abvc biopharma, inc. (nasdaq: abvc), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, cns, and ophthalmology, today announced enrollment progress in the phase ii part 2 clinical study of the company's adhd medicine, abv-1505, currently being conducted at five prestigious medical centers in taiwan. the part 2 study is a randomized, double-blind, placebo-controlled study, titled “a phase ii tolerability and efficacy study of pdc-1421 treatment in adult patients with attention-deficit hyperactivity disorder (adhd), part 2” and is expected to eventually enroll approximately 100 patients in taiwan and the united states.
ABVC Ratings Summary
ABVC Quant Ranking